Vitamin D supplementation increases survival in breast cancer treatment!
Breast cancer patients with high levels of vitamin D in their blood survive twice as long as breast cancer patients with lower levels, according to a new study published in the journal Anticancer Research. According to the National Institutes of Health, the current recommended daily amount of vitamin D is 600 IU for adults and 800 IU for people over 70. Researchers strongly recommend measuring vitamin D levels in breast cancer patients. Researchers at the University of California, San Diego School of Medicine, vitamin D and breast cancer The study he conducted on the relationship of Previous studies have shown that low vitamin D levels are linked to a higher risk of premenopausal breast cancer.
This finding provided important insights into the relationship between 25-hydroxyvitamin D, a metabolite produced by the body through the digestion of vitamin D, and breast cancer survival rates. The study performed a statistical analysis in five of the 25-hydroxyvitamin D studies, obtained at the time of breast cancer diagnosis and an average of nine years of follow-up. Combined, the studies included 4,443 breast cancer patients.
One of the authors of the study, Prof. Dr. Cedric Garland commented on the study: “Vitamin D metabolites increase communication between cells by activating a protein that blocks aggressive cell division. As long as vitamin D receptors are present, tumor growth is inhibited and its spread into the blood stream is inhibited. Vitamin D receptors are not lost until a tumor is very advanced. This is why patients with higher blood levels of vitamin D have better survival.”
In the study, women in the elevated serum group had an average level of 25-hydroxyvitamin D in their blood of 30 nanograms per milliliter (ng/ml). The mean of the low group was 17 ng/ml. The mean level of breast cancer patients in the USA is 17 ng/ml. Co-author of the study, Prof. Dr. “The study has implications for adding vitamin D as an adjuvant to conventional breast cancer therapy,” said Heather Hofflich.
Making suggestions in the light of the data obtained, Prof. Dr. Garland says that controlled clinical trials confirm the findings, but that it would also be helpful for physicians to consider adding vitamin D to the standard treatment of breast cancer patients already and then closely monitoring the patient.
What is folic acid? Benefits of folate vitamin and its use in pregnancy
prof. Dr. Garland concluded: “Since it is known that a safe dose of vitamin D should achieve high serum levels above 30 nanograms per milliliter, there is no compelling reason to wait for further studies to include vitamin D supplements in standard treatment regimens.”
prof. Dr. A 2011 meta-analysis by Garland and colleagues estimated that a serum level of 50 ng/ml was associated with 50% lower breast cancer. While there is some variation in absorption, those who consume 4,000 International Units (IU) of vitamin D daily from food or supplements will normally achieve a serum level of 50 ng/ml. prof. Dr. Garland cautions that patients should ask their healthcare professional to measure their levels before drastically increasing their vitamin D consumption.
According to the National Institutes of Health, the current recommended daily amount of vitamin D is 600 IU for adults and 800 IU for people over 70.
The full text of the article can be accessed from the link below.
Background/Aim: To determine whether higher serum 25-hydroxyvitamin D [25(OH)D] at diagnosis is associated with longer survival of patients with breast cancer.
Materials and Methods: A meta-analysis was performed of five studies of the relationship between 25(OH)D and mortality from breast cancer. A pooled hazard ratio was calculated using a random-effects model. The Der Simonian-Laird test was used to assess homogeneity.
Results: Higher serum concentrations of 25(OH)D were associated with lower case-fatality rates after diagnosis of breast cancer. Specifically, patients in the highest quintile of 25(OH)D had approximately half the death rate from breast cancer as those in the lowest.
Conclusion: High serum 25(OH)D was associated with lower mortality from breast cancer. Serum 25(OH)D in all patients with breast cancer should be restored to the normal range (30-80 ng/ml), with appropriate monitoring. Clinical or field studies should be initiated to confirm that this association was not due to reverse causation.